TipRanks
Advertisement
Advertisement

MX:BIIB Stock Latest News

Biogen price target raised to $270 from $240 at UBS
The FlyBiogen price target raised to $270 from $240 at UBS
5h ago
BIIB
Biogen price target lowered to $256 from $260 at RBC Capital
PremiumThe Fly
Biogen price target lowered to $256 from $260 at RBC Capital
1d ago
BIIB
Biogen Maintained at Buy as Analyst Sees Favorable Risk-Reward Ahead of Lupus Data; $256 Price Target Reaffirmed
PremiumRatings
Biogen Maintained at Buy as Analyst Sees Favorable Risk-Reward Ahead of Lupus Data; $256 Price Target Reaffirmed
3d ago
BIIB
ProMIS Neurosciences appoints Ivana Rubino as chief commercial officer
PremiumThe Fly
ProMIS Neurosciences appoints Ivana Rubino as chief commercial officer
3d ago
PMN
BIIB
Biogen says litifilimab demonstrates rapid, durable efficacy in Phase 2 data
PremiumThe Fly
Biogen says litifilimab demonstrates rapid, durable efficacy in Phase 2 data
7d ago
BIIB
Mizuho biotech analysts hold an analyst/industry conference call
PremiumThe FlyMizuho biotech analysts hold an analyst/industry conference call
8d ago
BBIO
BIIB
Biogen publishes results from adolescent subgroup of VALIANT study
Premium
The Fly
Biogen publishes results from adolescent subgroup of VALIANT study
22d ago
BIIB
Eisai, Biogen announce Leqembi Pen has been approved in Japan
Premium
The Fly
Eisai, Biogen announce Leqembi Pen has been approved in Japan
23d ago
BIIB
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
PremiumThe Fly
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
29d ago
GS
MS
Biogen price target raised to $175 from $165 at HSBC
PremiumThe Fly
Biogen price target raised to $175 from $165 at HSBC
29d ago
BIIB
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
PremiumThe Fly
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
1M ago
BIIB
STOK
Biogen price target raised to $245 from $225 at Piper Sandler
PremiumThe Fly
Biogen price target raised to $245 from $225 at Piper Sandler
1M ago
BIIB
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
PremiumThe FlyBiogen, Eisai announce NMPA of China approves subcutaneous Leqembi
1M ago
BIIB
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
Premium
The Fly
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
1M ago
BIIB
STOK
Biogen, Eisai announce positive recommendation for Leqembi in Canada
Premium
The Fly
Biogen, Eisai announce positive recommendation for Leqembi in Canada
1M ago
BIIB
Veeva price target raised to $310 from $270 at Needham
PremiumThe Fly
Veeva price target raised to $310 from $270 at Needham
1M ago
LLY
BIIB
Biogen price target raised to $260 from $240 at RBC Capital
PremiumThe Fly
Biogen price target raised to $260 from $240 at RBC Capital
2M ago
BIIB
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
PremiumThe Fly
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
2M ago
BIIB
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
PremiumThe Fly
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
2M ago
BIIB
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
PremiumThe FlyProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
2M ago
PMN
BIIB
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
Premium
The Fly
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
2M ago
BIIB
Wolfe upgrades Biogen to Outperform on late-stage pipeline
Premium
The Fly
Wolfe upgrades Biogen to Outperform on late-stage pipeline
2M ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >